Rosalind Advisors Inc. Increases Stake in COMPASS Pathways plc (NASDAQ:CMPS)

Rosalind Advisors Inc. boosted its position in shares of COMPASS Pathways plc (NASDAQ:CMPS) by 6.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 781,423 shares of the company’s stock after purchasing an additional 47,423 shares during the period. COMPASS Pathways comprises 3.1% of Rosalind Advisors Inc.’s holdings, making the stock its 13th biggest holding. Rosalind Advisors Inc.’s holdings in COMPASS Pathways were worth $4,923,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Blue Trust Inc. purchased a new stake in shares of COMPASS Pathways during the second quarter valued at $81,000. Green Alpha Advisors LLC purchased a new stake in shares of COMPASS Pathways in the 3rd quarter worth $99,000. Kennedy Capital Management LLC bought a new position in shares of COMPASS Pathways during the 1st quarter worth $139,000. Tidal Investments LLC increased its stake in shares of COMPASS Pathways by 43.6% during the first quarter. Tidal Investments LLC now owns 19,082 shares of the company’s stock valued at $159,000 after buying an additional 5,795 shares during the period. Finally, Chesapeake Capital Corp IL bought a new stake in shares of COMPASS Pathways in the first quarter valued at about $189,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of COMPASS Pathways in a research report on Monday, September 9th. HC Wainwright reduced their price objective on shares of COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Canaccord Genuity Group dropped their target price on COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, August 2nd. Royal Bank of Canada reduced their price target on COMPASS Pathways from $23.00 to $18.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Finally, Maxim Group reduced their target price on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a report on Friday, November 1st. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, COMPASS Pathways currently has a consensus rating of “Buy” and an average target price of $30.67.

Insider Buying and Selling

In related news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $6.05, for a total value of $16,093,000.00. Following the transaction, the insider now owns 6,905,774 shares in the company, valued at approximately $41,779,932.70. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.25% of the company’s stock.

COMPASS Pathways Price Performance

Shares of NASDAQ CMPS opened at $4.52 on Wednesday. The company has a market cap of $309.12 million, a PE ratio of -2.05 and a beta of 2.29. COMPASS Pathways plc has a fifty-two week low of $4.05 and a fifty-two week high of $12.75. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. The business has a 50-day simple moving average of $6.54 and a two-hundred day simple moving average of $7.02.

COMPASS Pathways (NASDAQ:CMPS) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.04. During the same quarter in the previous year, the business earned ($0.67) EPS. As a group, equities analysts expect that COMPASS Pathways plc will post -2.35 EPS for the current fiscal year.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.